Management of Elevated Liver Function Tests

Initial Diagnostic Workup

The American Gastroenterological Association recommends obtaining baseline comprehensive panel, including ALT, AST, alkaline phosphatase, total bilirubin with fractionation to determine direct bilirubin percentage, gamma-glutamyl transferase (GGT) or alkaline phosphatase isoenzymes to confirm hepatobiliary origin of elevated ALP, and INR to assess synthetic liver function 1
The American Society of Clinical Oncology suggests ruling out common etiologies, including viral hepatitis serologies, alcohol history, iron studies for hemochromatosis, imaging (ultrasound) to exclude biliary obstruction or liver metastases, and review all medications and supplements 2
The European Association for the Study of the Liver recommends confirming hepatic origin with GGT or 5'-nucleotidase before proceeding with hepatobiliary workup for isolated ALP elevation 3

The American College of Gastroenterology recommends continuing monitoring with repeat liver tests every 1-2 weeks until normalization for mild elevations (ALT <3× ULN or <1.5× baseline) 1
The American Society of Clinical Oncology suggests no treatment required for grade 1 elevations in most contexts 2
The American Association for the Study of Liver Diseases recommends holding potentially hepatotoxic agents immediately for moderate elevations (ALT 3-5× ULN or ≥3× baseline) 2, 1
The European Association for the Study of the Liver suggests initiating hepatology consultation for persistent or worsening elevations 2

The American College of Gastroenterology recommends permanently discontinuing the offending agent if any of the following occur: ALT ≥3× ULN with total bilirubin ≥2× ULN (Hy's Law criteria), development of severe hepatic symptoms, INR increases to >1.5 without other explanation, hepatic decompensation develops, or doubling of direct bilirubin from baseline 1

The American Association for the Study of Liver Diseases recommends using multiples of baseline rather than ULN for monitoring thresholds in patients with baseline liver disease 4, 5
The American Society of Clinical Oncology suggests holding immunotherapy temporarily and administering prednisone 0.5-1 mg/kg/day if no improvement after 3-5 days for Grade 2 (ALT 3-5× ULN) immune checkpoint inhibitor-related hepatitis 2
The European Association for the Study of the Liver recommends considering liver biopsy if steroid-refractory or if alternative diagnoses would alter management 2

The American College of Gastroenterology recommends not assuming elevated ALP is hepatic and always confirming with GGT or ALP isoenzymes 3, 1
The American Association for the Study of Liver Diseases suggests not continuing potentially hepatotoxic drugs while "monitoring" moderate-to-severe elevations—this risks progression to acute liver failure 1
The American Society of Clinical Oncology recommends not relying on aminotransferases alone in cirrhosis and monitoring bilirubin, INR, and clinical symptoms 4
The European Association for the Study of the Liver suggests not delaying hepatology referral for Grade 3 or higher elevations, Hy's Law criteria, or steroid-refractory cases 2, 1

The American College of Gastroenterology recommends monitoring every 1-2 days until improvement begins, then weekly until normalization for severe elevations 1
The American Association for the Study of Liver Diseases suggests monitoring every 3-7 days until consistent improvement, then every 1-2 weeks until normalization for moderate elevations 1